Results: 1-14 |
Results: 14

Authors: Saltz, L
Citation: L. Saltz, The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer - The Khayat et al article reviewed, ONCOLOGY-NY, 15(4), 2001, pp. 429-430

Authors: Kemeny, N Gonen, M Sullivan, D Schwartz, L Benedetti, F Saltz, L Stockman, J Fong, Y Jarnagin, W Bertino, J Tong, W Paty, P
Citation: N. Kemeny et al., Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer, J CL ONCOL, 19(10), 2001, pp. 2687-2695

Authors: Grann, A Feng, C Wong, D Saltz, L Paty, PP Guillem, JG Cohen, AM Minsky, BD
Citation: A. Grann et al., Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma, INT J RAD O, 49(4), 2001, pp. 987-995

Authors: Brentjens, R Saltz, L
Citation: R. Brentjens et L. Saltz, Islet cell tumors of the pancreas - The medical oncologist's perspective, SURG CL NA, 81(3), 2001, pp. 527

Authors: Nissan, A Guillem, JG Paty, PB Wong, WD Minsky, B Saltz, L Cohen, AM
Citation: A. Nissan et al., Abdominoperineal resection for rectal cancer at a specialty center, DIS COL REC, 44(1), 2001, pp. 27-35

Authors: Koea, JB Guillem, JG Conlon, KC Minsky, B Saltz, L Cohen, A
Citation: Jb. Koea et al., Role of laparoscopy in the initial multimodality management of patients with near-obstructing rectal cancer, J GASTRO S, 4(1), 2000, pp. 105-108

Authors: Chamberlain, RS Canes, D Brown, KT Saltz, L Jarnagin, W Fong, YM Blumgart, LH
Citation: Rs. Chamberlain et al., Hepatic neuroendocrine metastases: Does intervention alter outcomes?, J AM COLL S, 190(4), 2000, pp. 432-445

Authors: Saltz, L
Citation: L. Saltz, Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer, ONCOLOGY-NY, 14(12), 2000, pp. 47-50

Authors: Rosenthal, DI Haller, DG Saltz, L Semple, D Minsky, BD
Citation: Di. Rosenthal et al., Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin, ONCOLOGY-NY, 14(10), 2000, pp. 59-62

Authors: Schwartz, GK Ilson, D Saltz, L O'Reilly, E Tong, W Maslak, P Werner, J Perkins, P Stoltz, M Kelsen, D
Citation: Gk. Schwartz et al., Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma, J CL ONCOL, 19(7), 2000, pp. 1985-1992

Authors: Guillem, JG Puig-La Calle, J Akhurst, T Tickoo, S Ruo, L Minsky, BD Gollub, MJ Klimstra, DS Mazumdar, M Paty, PB Macapinlac, H Yeung, H Saltz, L Finn, RD Erdi, Y Humm, J Cohen, AM Larson, S
Citation: Jg. Guillem et al., Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography, DIS COL REC, 43(1), 2000, pp. 18-24

Authors: Rubin, J Ajani, J Schirmer, W Venook, AP Bukowski, R Pommier, R Saltz, L Dandona, P Anthony, L
Citation: J. Rubin et al., Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J CL ONCOL, 17(2), 1999, pp. 600-606

Authors: Ilson, DH Saltz, L Enzinger, P Huang, Y Kornblith, A Gollub, M O'Reilly, E Schwartz, G DeGroff, J Gonzalez, G Kelsen, DP
Citation: Dh. Ilson et al., Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer, J CL ONCOL, 17(10), 1999, pp. 3270-3275

Authors: Wagman, R Minsky, BD Cohen, AM Saltz, L Paty, PB Guillem, JG
Citation: R. Wagman et al., Conservative management of rectal cancer with local excision and postoperative adjuvant therapy, INT J RAD O, 44(4), 1999, pp. 841-846
Risultati: 1-14 |